OPNT - Opiant Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
15.25
+0.69 (+4.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.56
Open0.00
Bid0.00 x 0
Ask45.00 x 400
Day's Range14.68 - 15.50
52 Week Range8.77 - 51.90
Volume14,870
Avg. Volume22,571
Market Cap41.132M
Beta-0.33
PE Ratio (TTM)N/A
EPS (TTM)-1.48
Earnings DateMar 14, 2018 - Mar 19, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
Trade prices are not sourced from all markets
  • GlobeNewswire27 days ago

    Opiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

    Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today that it has received the first tranche of $500,000 from the previously awarded grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse for the development of OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose. “We are pleased to receive these initial funds from the NIH and are preparing to conduct key formulation studies of OPNT003,” said Roger Crystal, M.D., Chief Executive Officer of Opiant.  “Following completion of the formulation studies, we intend to initiate a confirmatory pharmacokinetic study which would position us to potentially submit an NDA for OPNT003 and intranasal delivery device combination, in 2020.  Based on the data generated to date, we believe OPNT003 will have a substantially longer half-life than naloxone, which has been previously approved by the FDA for treating suspected or confirmed opioid overdose.

  • GlobeNewswirelast month

    Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors

    Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the appointment of Richard J. Daly as a non-executive director and a member of the Audit Committee. Mr. Daly has supported the successful launch of 10 drugs during a 27-year career in the biotech and pharmaceutical industry.  With his appointment, the Opiant Board now consists of six members, four of whom are independent.

  • GlobeNewswire2 months ago

    Opiant Pharmaceuticals to Participate in Opioid Panel at the BIO International Convention

    Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that Roger Crystal, M.D., Opiant’s Chief Executive Officer, will participate in a panel at the BIO International Convention, being held June 4-7, 2018, in Boston, Massachusetts. The panel, which takes place on Tuesday, June 5, 2018, at 11:00 AM ET, will focus on understanding the biology underlying pain and addiction that are critical to supporting the discovery of novel and safer treatments for both pain and addiction, as well as for ensuring that patients receive the right treatment at the right time, with the right support, and without stigma.

  • GlobeNewswire2 months ago

    Opiant Pharmaceuticals to Participate in The American Society of Clinical Psychopharmacology 2018 Annual Meeting

    Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that Roger Crystal, M.D., Opiant’s Chief Executive Officer, and Phil Skolnick, Ph.D., Opiant’s Chief Scientific Officer, will participate in a panel session at the American Society of Clinical Psychopharmacology (ASCP) 2018 Annual Meeting, being held May 29 – June 1, 2018, in Miami Beach, Florida.  Dr. Skolnick will chair a panel session, titled: “The Opioid Epidemic: Crisis and Solutions,” and Dr. Crystal will be a speaker on the panel. Additionally, ASCP will present the 2018 “Donald Klein Lifetime Achievement Award” to Dr. Skolnick for his contributions to the field of neuropsychopharmacology.  Prior to his current role as Chief Scientific Officer of Opiant, Dr. Skolnick served as the Director, Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse, National Institutes of Health.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Opiant Pharmaceuticals, American Railcar Industries, Omega Flex, Johnson Outdoors, Thermon Group, and Connecticut Water Service — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, May 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Opiant ...

  • Zacks Small Cap Research2 months ago

    OPNT: KOL Event Highlights Medications for Addictions and Related Disorders

    Dr. Comer is a Professor of Neurobiology in the Department of Psychiatry at the College of Physicians and Surgeons at Columbia University. Dr. Comer began her talk with an overview of the epidemiology of the opioid epidemic. The following graphic shows the startling increase in drug overdose deaths from 1999 to 2016.

  • GlobeNewswire2 months ago

    Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update

    SANTA MONICA, Calif., May 08, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the first ...

  • GlobeNewswire3 months ago

    Opiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related Disorders

    Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, will host a Key Opinion Leader (KOL) luncheon on Medications for Addictions and Related Disorders on Thursday, May 10 in New York City. The event will feature presentations by KOLs Sandra Comer, PhD, Columbia University, Susan McElroy, MD, University of Cincinnati, and Stephanie O'Malley, PhD, Yale School of Medicine, who will discuss the current treatment landscape and unmet medical need for treating patients with substance use and eating disorders.

  • ACCESSWIRE3 months ago

    Blog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid Overdose

    LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Opiant Pharma, Inc. (NASDAQ: OPNT) ("Opiant"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OPNT as the Company's latest news hit the wire. On April 18, 2018, the Company, which is a specialty pharmaceutical organization developing pharmacological treatments for addictions, declared that the National Institutes of Health's National Institute on Drug Abuse (NIDA) has granted it an award of approximately $7.4 million for the development of OPNT003 (intranasal nalmefene) for opioid overdose.

  • ACCESSWIRE4 months ago

    Free Research Report as HubSpot’s Quarterly Earnings Surpassed Analysts’ Estimates

    Stock Monitor: Opiant Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free earnings report on HubSpot, Inc. (NYSE: HUBS ). If you want ...

  • Zacks Small Cap Research4 months ago

    OPNT: Opiant Developing New Opioid Overdose Treatment

    As part of the solution to the problem, the CDC recommends that the federal government “improve access to…overdose-reversing drugs, such as naloxone” and that health departments “increase naloxone distribution to first responders, family and friends, and other community members in affected areas” (CDC). While not a treatment for opioid dependence, health authorities believe that easy access to naloxone is an essential component of battling the ongoing opioid crisis due to its effectiveness in preventing overdose deaths. On February 12, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the development of OPNT003, a long-lasting opioid overdose treatment.

  • Reuters4 months ago

    Trump says he is working to lower prescription drug prices

    President Donald Trump promised to bring down prescription drug prices on Monday, saying U.S. citizens pay far more than people in other countries do for the same product and that his administration would announce new measures in about a month. "If you compare our drug prices to other countries in the world, in some cases it's many times higher for the exact same pill or whatever it is, in the exact same package made in the exact same plant," Trump said. Trump made the remarks during a speech in Manchester, New Hampshire that focused on the administration's efforts to battle the nation's opioid addiction crisis.

  • Reuters4 months ago

    As U.S. opioid crisis grows, Trump calls for death penalty for dealers

    President Donald Trump spelled out in new detail several steps he favors to fight a U.S. epidemic of opioid abuse, including the execution of drug dealers, a proposal that has gained little support from drug abuse and judicial experts. At an event in Manchester, New Hampshire, Trump unveiled an anti-opioid abuse plan, including his death penalty recommendation, new funding for other initiatives and stiffer sentencing laws for drug dealers.

  • Zacks Small Cap Research5 months ago

    OPNT: Developing Longer-Acting Opioid Overdose Treatment

    On February 12, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the development of OPNT003, a long-lasting opioid overdose treatment. OPNT003 is an intranasal formulation of nalmefene, a naltrexone derivative. The U.S. continues to battle an opioid epidemic.

  • Insider Q&A: Narcan exec talks merits of spray for overdoses
    Associated Press7 months ago

    Insider Q&A: Narcan exec talks merits of spray for overdoses

    Dr. Roger Crystal's company was struggling to find new uses for an old drug that reverses overdoses. Then the opioid epidemic hit. Naloxone had first gone on sale in 1971 but was injected with a syringe. ...

  • Zacks Small Cap Research7 months ago

    OPNT: Will Begin Receiving 90% of NARCAN® Nasal Spray Royalties in 1Q18

    On December 20, 2017, Opiant Pharmaceuticals, Inc. (OPNT) announced that it expects to begin receiving 90% of royalty and milestone payments related to the sale of NARCAN® Nasal Spray beginning in the first quarter of 2018. On December 15, 2016, Opiant Pharmaceuticals, Inc. (OPNT) announced an agreement with SWK Holdings Corporation whereby SWK acquired the rights to certain royalty and milestone payments related to the sale of NARCAN® Nasal Spray for an initial payment of $13.7 million and the potential for an additional $3.75 million if certain future net sales milestones were met.